Tratamiento de la enfermedad de Alzheimer
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
##plugins.themes.bootstrap3.displayStats.downloads##
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Jorm AF, Jolley D. The incidence ofdementia: a meta-analysis. Neurology 1998;51(3):728-33.
Mann DM, Marcyniuk B, Yates PO, et al.The progression of the pathological changes ofAlzheimer’s disease in frontal and temporalneocortex examined both at biopsy and atautopsy. Neuropathol Appl Neurobiol 1988;14(3):177-95.
Joachim CL, Morris JH, Selkoe DJ. Diffusesenile plaques occur commonly in thecerebellum in Alzheimer’s disease. Am J Pathol1989; 135(2):309-19.
Braak H, Braak E. Neuropathologicalstageing of Alzheimer-related changes. ActaNeuropathol (Berl) 1991; 82(4):239-59.
Delacourte A, David JP, Sergeant N, et al.The biochemical pathway of neurofibrillarydegeneration in aging and Alzheimer’s disease.Neurology 1999; 52(6):1158-65.
Hyman BT, Van Hoesen GW, Damasio AR,et al. Alzheimer’s disease: cell-specificpathology isolates the hippocampal formation.Science 1984; 225(4667):1168-70.
Baskin DS, Browning JL, Pirozzolo FJ, etal. Brain choline acetyltransferase and mentalfunction in Alzheimer disease. Arch Neurol1999; 56(9):1121-3.
Schroder H, Zilles K, Luiten PG, et al.Human cortical neurons contain both nicotinicand muscarinic acetylcholine receptors: animmunocytochemical double-labeling study.Synapse 1989; 4(4):319-26.
Flynn DD, Ferrari-DiLeo G, Levey AI, et al.Differential alterations in muscarinic receptorsubtypes in Alzheimer’s disease: implicationsfor cholinergic-based therapies. Life Sci 1995;56(11-12):869-76.
Xu H, Sweeney D, Greengard P, et al.Metabolism of Alzheimer beta-amyloidprecursor protein: regulation by protein kinaseA in intact cells and in a cell-free system. ProcNatl Acad Sci U S A 1996; 93(9):4081-4.
Klunk WE, Debnath ML, Koros AM, et al.Chrysamine-G, a lipophilic analogue of Congored, inhibits A beta-induced toxicity in PC12cells. Life Sci 1998; 63(20):1807-14.
Lee VM. Regulation of tau phosphorylationin Alzheimer’s disease. Ann N Y Acad Sci 1996;777:107-13.
Morgan D. Immunotherapy for Alzheimer’sdisease. J Alzheimers Dis 2006; 9(3 Suppl):425-32.
Pappolla MA, Bryant-Thomas TK, HerbertD, et al. Mild hypercholesterolemia is an earlyrisk factor for the development of Alzheimeramyloid pathology. Neurology 2003; 61(2):199-205.
Rea TD, Breitner JC, Psaty BM, et al. Statinuse and the risk of incident dementia: theCardiovascular Health Study. Arch Neurol2005; 62(7):1047-51.
Sidera C, Parsons R, Austen B. Theregulation of beta-secretase by cholesterol andstatins in Alzheimer’s disease. J Neurol Sci2005; 229-230:269-73.
McGeer PL, Schulzer M, McGeer EG.Arthritis and anti-inflammatory agents aspossible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies.Neurology 1996; 47(2):425-32
Mrak RE, Sheng JG, Griffin WS. Glialcytokines in Alzheimer’s disease: review andpathogenic implications. Hum Pathol 1995;26(8):816-23.
Aisen PS, Davis KL. Inflammatorymechanisms in Alzheimer’s disease:implications for therapy. Am J Psychiatry 1994;151(8):1105-13.
Kuller LH, Tracy RP, Shaten J, et al. Relationof C-reactive protein and coronary heart diseasein the MRFIT nested case-control study.Multiple Risk Factor Intervention Trial. Am JEpidemiol 1996; 144(6):537-47.
Rogers J, Kirby LC, Hempelman SR, et al.Clinical trial of indomethacin in Alzheimer’sdisease. Neurology 1993; 43(8):1609-11.
Urani A, Privat A, Maurice T. Themodulation by neurosteroids of thescopolamine-induced learning impairment inmice involves an interaction with sigma1(sigma1) receptors. Brain Res 1998; 799(1):64-77.
Shumaker SA, Legault C, Kuller L, et al.Conjugated equine estrogens and incidence ofprobable dementia and mild cognitiveimpairment in postmenopausal women:Women’s Health Initiative Memory Study.JAMA 2004; 291(24):2947-58.
Birks J, Harvey RJ. Donepezil for dementiadue to Alzheimer’s disease. Cochrane DatabaseSyst Rev 2006; (1):CD001190.
Birks J. Cholinesterase inhibitors forAlzheimer’s disease. Cochrane Database SystRev 2006 Jan 25; (1):CD005593.
Duvoisin RC, Katz R. Reversal of centralanticholinergic syndrome in man byphysostigmine. JAMA 1968; 206(9):1963-5.
Summers WK, Majovski LV, Marsh GM, etal. Oral tetrahydroaminoacridine in long-termtreatment of senile dementia, Alzheimer type.N Engl J Med 1986; 315(20):1241-5.
Qizilbash N, Birks J, Lopez Arrieta J, et al.Tacrine for Alzheimer’s disease. CochraneDatabase Syst Rev 2000; (3):CD000202.
Cummings JL. Cholinesterase inhibitors: Anew class of psychotropic compounds. Am JPsychiatry 2000; 157(1):4-15.
Golimstok A y col. Predictores de respuestaal tratamiento con tacrina en enfermedad deAlzheimer [abstract]. Rev Neurol Argent 1996.
Grupo de trabajo de Neurología delComportamiento y Neurociencias Cognitivas.Guía de práctica clínica en la Enfermedad deAlzheimer. Rev Neurol Argent 2006; 31(2):140-4.
Davidson M, Stern RG, Bierer LM, et al.Cholinergic strategies in the treatment ofAlzheimer’s disease. Acta Psychiatr ScandSuppl 1991; 366:47-51.
Fioravanti M, Yanagi M. Cytidinediphos-phocholine (CDP-choline) for cognitive andbehavioural disturbances associated withchronic cerebral disorders in the elderly.Cochrane Database Syst Rev 2005; (2):CD000269.
Sano M, Ernesto C, Thomas RG, et al. Acontrolled trial of selegiline, alpha-tocopherol,or both as treatment for Alzheimer’s disease.The Alzheimer’s Disease Cooperative Study. NEngl J Med 1997; 336(17):1216-22
Masaki KH, Losonczy KG, Izmirlian G, etal. Association of vitamin E and C supplementuse with cognitive function and dementia inelderly men. Neurology 2000; 54(6):1265-72.
Mohr E, Schlegel J, Fabbrini G, et al.Clonidine treatment of Alzheimer’s disease.Arch Neurol 1989; 46(4):376-8.
Winblad B, Poritis N. Memantine in severedementia: results of the 9M-Best Study (Benefitand efficacy in severely demented patientsduring treatment with memantine). Int J GeriatrPsychiatry 1999; 14(2):135-46.
Tariot PN, Farlow MR, Grossberg GT, et al.Memantine treatment in patients with moderateto severe Alzheimer disease already receivingdonepezil: a randomized controlled trial. JAMA2004; 291(3):317-24.
Cummings JL, Schneider E, Tariot PN, etal. Behavioral effects of memantine inAlzheimer disease patients receiving donepeziltreatment. Neurology 2006; 67(1):57-63.
Croisile B, Trillet M, Fondarai J, et al. Long-term and high-dose piracetam treatment ofAlzheimer’s disease. Neurology 1993;43(2):301-5.
Oken BS, Storzbach DM, Kaye JA. Theefficacy of Ginkgo biloba on cognitive functionin Alzheimer disease. Arch Neurol 1998;55(11):1409-15.
Taylor JE. Liaisons des neuromediateurs aleurs recepteurs dans le cerveau de rats. Effet del’administration chronique de l’extrait de Ginkgobiloba. Presse Med 1986; 15(31):1491-3.
Mangone CA. Enfermedad de Alzheimer.En: Micheli F, Nogués MA, Asconapé JJ, et al.Tratado de neurología clínica. Buenos Aires:Panamericana, 2002.
Crapper McLachlan DR, Dalton AJ, KruckTP, et al. Intramuscular desferrioxamine inpatients with Alzheimer’s disease. Lancet 1991;337(8753):1304-8. Errata en: Lancet 1991;337(8757):1618.